digitoxigenin-bis(digitoxoside): metabolite of digitoxin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 27886 |
MeSH ID | M0114974 |
Synonym |
---|
einecs 240-533-8 |
brn 0101942 |
digitoxigenin di(digitoxoside) |
5-beta-card-20(22)-enolide, 3-beta,14-dihydroxy-, didigitoxoside |
3beta-((2,6-dideoxy-4-o-(2,6-dideoxy-beta-d -ribo-hexopyranosyl)-beta-d -ribo-hexopyranosyl)oxy)-14-hydroxy-5beta-card-20(22)-enolide |
digitoxigenine bis-digitoxoside |
digitoxigenin 3-o-bisdigitoxoside |
5-beta-card-20(22)-enolide, 3-beta-((o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4))oxy)-14-hydroxy- |
digitoxin digitoxoside |
digitoxigenin-bis(digitoxoside) |
3-[(3s,5r,10s,13r,14s,17r)-3-[(2r,4s,5s,6r)-5-[(2s,4s,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one |
4-18-00-01478 (beilstein handbook reference) |
DTXSID20936993 |
3-{[2,6-dideoxy-4-o-(2,6-dideoxyhexopyranosyl)hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide |
Excerpt | Reference | Relevance |
---|---|---|
" However, the mean bioavailability of unchanged bisdigitoxoside was only 56." | ( Bioavailability of the bis- and monodigitoxosides of digitoxigenin. Fenster, PE; Graves, PE; MacFarland, RT; Marcus, FI; Perrier, D, 1985) | 0.27 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 9 (90.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.79) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |